Senior Scientist (R3), AI/ML Molecular Drug Design

Merck & Co. is seeking a highly experienced and innovative Senior Scientist (R3) to join our AI/ML Molecular Drug Design team. The ideal candidate will have an advanced degree in relevant disciplines such as computational biology, machine learning, bioinformatics, or a related field, as well as a strong background in the principles, methods, and techniques of AI/ML molecular drug design. The successful candidate will have the drive and enthusiasm to lead a team of scientists with the shared goal of leveraging AI/ML techniques to design new drugs and therapies to improve the health of individuals, families, and communities. They will have a passion for problem solving and will be able to work effectively in a fast-paced environment. We are looking for an individual with strong communication and interpersonal skills and the ability to interact with a diverse group of stakeholders. This position is based at our headquarters in Kenilworth, NJ and offers a competitive salary and benefits package. If you are excited to join a world-class team and help us create the future of healthcare, we welcome your application.

According to JobzMall, the average salary range for a Senior Scientist (R3), AI/ML Molecular Drug Design in San Francisco, CA, USA is $133,000 - $157,000 per year. This range is based on the average salary of similar positions in the same area.

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures.